Browsing by Author "Tegegne, Mulugeta Gelaw"

Now showing 1 - 1 of 1
  • Thumbnail Image
    ItemOpen Access
    Evaluation of serum antibody titers, proliferative responses and cytokines after prime-boost immnization of balb/c mice with different formulations of pxn-1 and sod-b1 vaccine candidates from leishmania donovani complex parasites
    (2008) Tegegne, Mulugeta Gelaw; Gedamu, Lashitew
    Leishmaniasis is a vector borne disease that 1s caused by a protozoan parasite, Leishmania. With an estimated 350 million people at risk, a worldwide prevalence of 12 million and 2 million new reports each year, the world health organization (WHO) marked leishmaniasis as one of the most serious, epidemic prone infectious diseases of our time. Because of lack of effective treatment and the issue of feasibility with other control measures, vaccination remains the best hope for control of all forms of leishmaniasis. Peroxidoxins and Superoxide Dismutases are antioxidants, and are potential vaccine candidates tested in many disease systems including leishmaniasis. However, there are no reports on Pxnl and SODBl from L. donovani complex parasites that cause fatal visceral leishmaniasis, as vaccine candidates. Here in our study we demonstrated that a prime/boost strategy based on Pxnl and SODBl from L. donovani complex parasites, both in DNA/DNA and DNA/Protein strategies (for Pxnl) and DNA/Protein strategy (for SODBl ) is immunogenic and showed humoral and specific T cell, and cytokine responses suggestive of a predominant Thl, but not Th2, like response in Balb/c mice. In both strategies, albeit a varying scale of response, a Thl phenotypic response, characterized by in vitro lymphocyte proliferation, IFN-y production and IgG2a antibodies, was observed with negligible IL-10 production. Future protection studies in mice and antigenic studies on human samples are required to expand the results.